BMP1
Bone morphogenetic protein 1
Protein Summary
Cleaves the C-terminal propeptides of procollagen I, II and III. Induces cartilage and bone formation. May participate in dorsoventral patterning during early development by cleaving chordin (CHRD). Responsible for the proteolytic activation of lysyl oxidase LOX. This gene encodes a protein that is capable of inducing formation of cartilage in vivo. Although other bone morphogenetic proteins are members of the TGF-beta superfamily, this gene encodes a protein that is not closely related to other known growth factors. This gene is expressed as alternatively spliced variants that share an N-terminal protease domain but differ in their C-terminal region. [provided by RefSeq, Aug 2008]
- ENST00000306349
- ENSP00000306121
- ENSG00000168487
- ENST00000306385
- ENSP00000305714
- ENST00000471755
- ENSP00000428665
- ENST00000520970
- ENSP00000428332
- ENST00000521385
- ENSP00000430406
- PCOLC
- PCP
- TLD
- OI13
- PCP2
- PCOLC
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
protein domain | 1 | ||
PubMedID | 0.95 | ||
disease perturbation | 0.83 | ||
transcription factor perturbation | 0.68 | ||
molecular function | 0.67 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 372.73 (req: < 5)
Gene RIFs: 70 (req: <= 3)
Antibodies: 276 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 372.73 (req: >= 5)
Gene RIFs: 70 (req: > 3)
Antibodies: 276 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 18
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 307
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0